ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025
A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05025800 (A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients With Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients With Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma
Who cites it
9 citing papers in PubMed.
- CD47-mediated efferocytosis in diseases: A comprehensive review.Molecular biology reports · 2026Review
- Tissue-Resident Macrophage in Inflammation and Cancer.MedComm · 2026Review
- Mechanisms of resistance to macrophage checkpoint inhibitors in B-cell non-Hodgkin lymphoma.British journal of haematology · 2026Article
- Selective Targeting of Immune Checkpoints HLA-G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma.Expert opinion on investigational drugs · 2026Review
- Article
- Macrophage phagocytosis checkpoints in DLBCL immunotherapy: an evidence-maturity framework from CD47 to CD200.Frontiers in oncology · 2026Review
- Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study.Haematologica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
purposeSIRPα+ macrophages can mediate resistance to lenalidomide and rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL). Evorpacept (ALX148) is a novel CD47 blocker that abrogates interactions between lymphoma cells and SIRPα+ macrophages. PATIENTS AND
methodsAdult patients with B-NHL who had received at least two prior lines of systemic therapy were included in this single-arm phase I study (NCT05025800). Evorpacept was administered intravenously, in a 28-day cycle, until progression at two dose levels (DL): 30 mg/Kg on day (D) 1 and D15 (DL1) or 60 mg/Kg on day 1 (DL2); rituximab 375 mg/m2 i.v. was given weekly during cycle 1 and on D1 during cycles 2 to 6; and lenalidomide 20 mg was given orally from D1 to D21 during cycles 1 to 6. Single-cell RNA sequencing was performed on tumor biopsies collected before treatment and during cycle 1.
resultsTwenty patients were included in this study. The median age was 61 (27-85) years, and 18 patients (90%) had indolent B-NHL. Three patients were treated at DL1, 17 at DL2, and no dose-limiting toxicity was observed. The most common grade 3 to 4 adverse events included neutropenia (60%), infections (30%), and alanine transferase increase (15%). Sixteen (80%) patients achieved complete response, and after a median follow-up of 28 months, 2-year progression-free survival rate was 69%. During treatment, a significant increase in T cells and macrophages was observed, and macrophage pathways associated with anti-tumoral activity were upregulated.
conclusionsEvorpacept plus lenalidomide and rituximab has a safe toxicity profile and promising anti-tumoral activity, and induces favorable biological effects on the tumoral immune microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.